[IBRX] ImmunityBio, Inc. $8.47
52-wk High $12.43
📌 Investment Snapshot
- 💰 Price & Valuation: IBRX trades at $8.47, with a N/A P/E ratio, reflecting its early-stage growth profile in biotechnology.
- 📈 Latest Quarter: Q4 FY25 revenue soared +407.0% YoY to $38M, indicating strong commercial traction.
- 🔑 #1 Catalyst: Progress in its NANT Cancer Vaccine platform and regulatory approvals for key pipeline assets could unlock substantial value.
- 🎯 Consensus: STRONG BUY rating with a $15 mean target, implying +77.1% upside from current levels.
| 📍 Entry Zone | $8.00 or below | 🛑 Stop-Loss | $6.90 |
| 📋 Adjust If | RSI rebounds above 50 without significant price appreciation | ||
The Investment Case — Why Now?
ImmunityBio has demonstrated a significant turnaround in its commercial performance, with Q4 FY25 revenue soaring +407.0% year-over-year to $38M. This surge, following several quarters of substantial growth, suggests a strong trajectory for its NANT Cancer Vaccine platform and other pipeline assets. The stock’s current RSI of 29.7 indicates it is oversold, presenting a potential entry point for investors looking to capitalize on this growth momentum and the substantial +77.1% analyst upside.
However, the primary risk for ImmunityBio remains its path to profitability. Despite impressive revenue growth, the company continues to report negative EPS (TTM: $-0.38), indicating ongoing cash burn. Sustained unprofitability and the need for further capital raises could dilute shareholder value and pressure the stock, especially if regulatory approvals or commercialization efforts face unexpected delays.
Company Overview
| Detail | Value |
|---|---|
| Company | ImmunityBio, Inc. |
| Ticker / Exchange | IBRX / NYSE / NASDAQ |
| Sector / Industry | Healthcare / Biotechnology |
Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| IBRX | (This stock) | N/A |
| S&P 500 Avg | S&P 500 Avg | 21.0x |
| UNH | UnitedHealth Group Incorporate | 20.8x |
| JNJ | Johnson & Johnson | 21.3x |
| LLY | Eli Lilly and Company | 39.5x |
| PFE | Pfizer, Inc. | 19.8x |
Price Action & Technicals
$8.47
-2.6%
+305.3%
-31.9%
Neutral
ImmunityBio’s current price of $8.47 is significantly above its SMA 50-day of $7.1 and SMA 200-day of $3.63, indicating a strong upward trend over the medium and long term, despite recent pullback. The RSI of 29.7 suggests the stock is currently oversold, presenting a potential bounce opportunity, while the MACD indicates a neutral short-term momentum. The price sits at 35.2% within its Bollinger Bands, closer to the lower band, reinforcing the oversold signal.
Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q4 FY25 | $38M | N/A | +407.0% |
| Q3 FY25 | $32M | $-0.07 | +425.1% |
| Q2 FY25 | $26M | $-0.10 | +2423.9% |
| Q1 FY25 | $17M | $-0.15 | +41192.5% |
Growth Drivers — What Moves the Stock
- NANT Cancer Vaccine Platform: Continued positive clinical trial results and eventual regulatory approvals for its innovative cancer therapies, particularly the NANT Cancer Vaccine, will be a primary driver of future revenue and stock appreciation. (🟢 Upside Surprise Potential)
- Accelerating Revenue Growth: The recent quarters have shown explosive revenue growth, with Q4 FY25 up +407.0% YoY. Maintaining or accelerating this commercial momentum through successful product launches and market penetration will be key. (🟢 Upside Surprise Potential)
- Biotechnology Sector Tailwinds: The broader biotechnology sector benefits from increasing healthcare spending, advancements in genetic engineering, and a growing demand for novel therapeutic solutions, providing a favorable operating environment for ImmunityBio. (🟡 Already Priced In)
Smart Money & Institutional Positioning
Institutional Holdings (Top 5)
| Institution | Shares (K) |
|---|---|
| Vanguard Group Inc | 32,777 |
| Blackrock Inc. | 25,601 |
| State Street Corporation | 16,455 |
| Jane Street Group, LLC | 14,224 |
| Geode Capital Management | 7,920 |
Holdings reflect most recent 13F (45-day lag). QoQ change not available.
Short Interest
| Metric | Value |
|---|---|
| Short % of Float | 35.41% |
| Days to Cover | 3.5 |
The high short interest of 35.41% indicates a significant bearish bet against IBRX, but also presents a potential short squeeze catalyst if positive news emerges.
Key Risk Factors — Risk Matrix
Regulatory & Approval Risk
Biotech companies face stringent regulatory hurdles, and any delays or rejections for ImmunityBio’s pipeline drugs could severely impact future revenue and investor confidence.
~$15B+ impact
Intense Competition
The oncology market is highly competitive, with numerous large pharmaceutical companies and emerging biotechs vying for market share, potentially limiting ImmunityBio’s growth.
~$10B impact
Cash Burn & Profitability
ImmunityBio is currently unprofitable, and continued high R&D and commercialization expenses could lead to further cash burn, necessitating additional financing and potential dilution.
~$15B+ impact
Pipeline Failure
The success of ImmunityBio hinges on its drug pipeline. Failure in late-stage clinical trials or unexpected safety issues could lead to significant write-downs and a loss of market value.
~$15B+ impact
Guidance & Wall Street View
Recent Analyst Actions
| Firm | Rating | Price Target | Date | Action |
|---|---|---|---|---|
| D. Boral Capital | Buy | $23.00 | 2026-03-17 | Maintain |
| Piper Sandler | Overweight | $12.00 | 2026-03-04 | Reiterate |
| HC Wainwright & Co. | Buy | $15.00 | 2026-02-23 | Maintain |
| BTIG | Buy | $9.00 | 2026-01-23 | Maintain |
| Jefferies | Buy | $9.00 | 2025-12-12 | Maintain |
Consensus Price Target Distribution
| High Target | Mean Target | Low Target | Total Analysts | Consensus Rating |
|---|---|---|---|---|
| $23 | $15 | $11 | 5 | STRONG_BUY |
Wall Street analysts maintain a STRONG BUY consensus for ImmunityBio, with a mean price target of $15, representing a substantial +77.1% upside from the current price. The target range, from a low of $11 to a high of $23, indicates strong confidence in the company’s long-term potential.
Bull vs Bear — Probability-Weighted Scenarios
Bull Case
- Successful Phase 3 clinical trials and rapid regulatory approval for key cancer therapies, leading to accelerated commercialization and market penetration beyond current expectations.
- Continued explosive revenue growth, driven by strong adoption of its NANT Cancer Vaccine platform, leading to faster-than-anticipated path to profitability.
Implied Price Target: $18 – $23
Base Case
ImmunityBio continues its strong revenue growth, but at a more moderate pace than the bull case, facing some competition and regulatory delays. Profitability remains elusive in the near-term, requiring careful cash management. The stock trades in line with analyst consensus, reflecting its growth potential balanced against ongoing operational challenges.
Implied Fair Value: $12 – $15
Bear Case
- Significant setbacks in clinical trials or unexpected regulatory rejections for key pipeline assets, leading to a loss of investor confidence and a re-evaluation of the company’s long-term prospects.
- Increased cash burn and the necessity for dilutive financing rounds, coupled with intensified competition, erode market share and prevent the company from achieving profitability.
Implied Downside Target: $6 – $9
Disclaimer & Hashtags
This Veqtio analysis is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. All investment decisions should be made with the advice of a professional financial advisor. Veqtio is not responsible for any losses incurred as a result of using this information.
#IBRX #ImmunityBio #USStocks #StockAnalysis #Veqtio #Biotechnology #Healthcare #NANTCancerVaccine